ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

European Centre for Disease Prevention and ControlAlthough SARS-CoV-2 transmission remains widespread in large parts of the EU/EEA, most countries report declining trends in 14-day COVID-19 notification rates, hospital and intensive care unit...
ECDC - Countering online vaccine misinformation in the EU/EEA

ECDC - Countering online vaccine misinformation in the EU/EEA

European Centre for Disease Prevention and ControlVaccines authorised by the European Medicines Agency for use in the European Union (EU) are known to be safe and effective in preventing infectious diseases. Nonetheless, misinformation that...
JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA NETWORKOn December 20, 2020, Israel initiated a national vaccination program against COVID-19. One prioritized group was health care workers, many of whom are breastfeeding women. Despite the fact that the vaccine trial did not include...
NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

The New England Journal of MedicineThe B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has...
BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children

BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children

British Medical JournalAs the majority of adults in multiple rich western countries have now received at least one dose of a covid-19 vaccine, the focus is turning to children. While there is wide recognition that children’s risk of severe...
NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

The New England Journal of MedicineInformation is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome...
NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England Journal of MedicinePatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment...
ECDC - Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern

ECDC - Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern

European Centre for Disease Prevention and ControlBased on the available evidence, the SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) is 40-60% more transmissible than the Alpha (Β.1.1.7) VOC and may be associated with higher risk of...
ECDC - Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions

ECDC - Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions

European Centre for Disease Prevention and Control

As they respond to the COVID-19 pandemic, countries worldwide have increasingly looked to digital technologies in support of public health measures for contact tracing. 

CDC - Interim Guidance for Antigen Testing for SARS-CoV-2

CDC - Interim Guidance for Antigen Testing for SARS-CoV-2

Centers for Disease Control and PreventionThis interim guidance is intended for healthcare providers who order antigen tests, receive antigen test results, or perform point-of-care testing, as well as for laboratory professionals who...
BMJ - How long does covid-19 immunity last?

BMJ - How long does covid-19 immunity last?

British Medical JournalHow long does covid-19 immunity last? This is difficult to say definitively. When the body’s immune system responds to an infection, it isn’t always clear how long any immunity that develops will persist. Covid-19 is a very...
BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ - Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

British Medical JournalTo estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital,...
THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

THE LANCET - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

The LancetMany patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
ECDC - Considerations for the use of saliva as sample material for COVID-19 testing

ECDC - Considerations for the use of saliva as sample material for COVID-19 testing

European Centre for Disease Prevention and Control

Nasopharyngeal specimens remain the gold standard for COVID-19 testing for use with RT-PCR and rapid antigen diagnostic tests.

ECDC - Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings

ECDC - Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings

European Centre for Disease Prevention and ControlThe use of rapid antigen detection tests (RADTs) and/or self-test RADTs in occupational settings can complement, but not replace, occupational safety and health measures and existing...
1345678910Último
Eventos
«setembro de 2021»
segterquaquisexsábdom
303112345
6789101112
13141516171819
20212223242526
2728
Dia 28 de setembro às 17h00

Dia 28 de setembro às 17h00

A chill out session prevista para dia 24 de setembro ao fim da tarde foi adiada, tendo em conta a previsão meteorológica. Assim, passará a realizar-se no dia 28 de setembro, a partir das 17h00, no Jardim da Ordem dos Médicos, em Lisboa. A sessão inclui uma apresentação da médica e cantora Catarina Munhá, a partir das 18h00.

Ler mais
2930123
45678910
Categorias

Categorias

Arquivo de Notícias

Arquivo